Bioven Sdn. Bhd.
🇲🇾Malaysia
Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer (NSCLC) Stages IIIB/IV
Phase 2
Terminated
- Conditions
- Non-small-cell Lung Cancer (NSCLC) Stage IIIb/IV
- Interventions
- Biological: Recombinant Human rEGF-P64K/Montanide Vaccine
- First Posted Date
- 2007-08-15
- Last Posted Date
- 2011-09-30
- Lead Sponsor
- Bioven Sdn. Bhd.
- Target Recruit Count
- 230
- Registration Number
- NCT00516685
- Locations
- 🇲🇾
Local Institution, Kuala Lumpur, Malaysia
© Copyright 2025. All Rights Reserved by MedPath